Impax Asset Management Group’s Charles River Laboratories CRL Stock Holding History

Impax Asset Management Group’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,115	Closed	-$264K	–	317
2023 Q4	$264K	Sell	1,115 -1,987	-64%	-$391K	﹤0.01%	359
2023 Q3	$608K	Sell	3,102 -141	-4%	-$28.9K	﹤0.01%	313
2023 Q2	$682K	Sell	3,243 -39	-1%	-$7.76K	﹤0.01%	311
2023 Q1	$662K	Buy	3,282 +1,127	+52%	+$255K	﹤0.01%	304
2022 Q4	$470K	Buy	+2,155	New	+$471K	﹤0.01%	323
2022 Q3	–	Sell	-945	Closed	-$202K	–	397
2022 Q2	$202K	Hold	945	–	–	﹤0.01%	384
2022 Q1	$268K	Sell	945 -5	-0.5%	-$1.54K	﹤0.01%	387
2021 Q4	$358K	Sell	950 -26	-3%	-$10.1K	﹤0.01%	363
2021 Q3	$403K	Hold	976	–	–	﹤0.01%	342
2021 Q2	$361K	Hold	976	–	–	﹤0.01%	352
2021 Q1	$283K	Buy	+976	New	+$271K	﹤0.01%	368

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Impax Asset Management Group's CRL Position: Q1 2024 in Review

Impax Asset Management Group sold out of Charles River Laboratories (CRL) in Q1 2024, closing a stake of 1,115 shares — an estimated $264K sold.

Impax Asset Management Group first reported a position in CRL in Q1 2021 and held it in 11 quarters. The position peaked at $682K in Q2 2023. 676 funds tracked by Wall St. Rank hold CRL as of Q1 2024.

Impax Asset Management Group reported no remaining Charles River Laboratories position as of Q1 2024 after selling out during the quarter.
Impax Asset Management Group sold 1,115 Charles River Laboratories shares in Q1 2024, an estimated $264K.
Impax Asset Management Group first reported a position in Charles River Laboratories in Q1 2021 and held it in 11 quarters.
Impax Asset Management Group's Charles River Laboratories position peaked at $682K in Q2 2023.
676 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2024.

Based on Impax Asset Management Group's 13F filing for Q1 2024, filed 30 Apr 2024.